Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

265 trials

2024-514152-32-00
Recruiting
A Study to Test How Safe, Effective and How the Body Responds to the Combination of Mosunetuzumab and Pirtobrutinib Together to Treat Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Phase 1 · Spain, France, Poland · 8 sites
Registry update: 13 Jul 2026
NCT06520098
Recruiting
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Phase 2 · United States · 4 sites
Registry update: 30 Oct 2026
NCT07205315
Recruiting
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
Early phase 1 · China · 2 sites
Registry update: 20 Jul 2026
NCT07154264
Recruiting
A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
Phase 2 · China · 15 sites
Registry update: 22 Jun 2026
NCT07139873
Recruiting
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
Phase 3 · China, Italy, Poland · 24 sites
Registry update: 3 Jun 2026
NCT06973187
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 3 · Argentina, Austria, Australia, Belgium, Brazil, Switzerland, China, Germany, Spain, France, United Kingdom, Israel, Italy, Japan, South Korea, Mexico, Netherlands, New Zealand, Poland, Puerto Rico, Romania, Sweden, Singapore, United States · 217 sites
Registry update: 28 Sept 2026
NCT06712810
Recruiting
Q702 for the Treatment of Patients With Hematologic Malignancies
Phase 1 · United States · 2 sites
Registry update: 10 Oct 2025
NCT06859008
Recruiting
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Phase 1 · United States · 1 site
Registry update: 20 Apr 2026
NCT07108998
Recruiting
Study of Epcoritamab as a Consolidation Therapy in CLL/SLL
Phase 2 · United States · 1 site
Registry update: 6 Jan 2026
NCT06735664
Recruiting
Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation
Phase 1 · United States · 1 site
Registry update: 16 Sept 2026
NCT07763054
Recruiting
Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients
Not applicable · China · 1 site
Registry update: 13 Aug 2026
NCT06859424
Recruiting
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Phase 2 · United States · 13 sites
Registry update: 17 Mar 2026
NCT07030400
Recruiting
Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma
Not applicable · United States · 1 site
Registry update: 1 Apr 2026
NCT06967610
Recruiting
Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
Phase 2 · United States · 1 site
Registry update: 3 Nov 2026
NCT06916767
Recruiting
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
Phase 1 · United States · 1 site
Registry update: 10 Nov 2025
2023-510294-34-00
Recruiting
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)
Phase 3 · Austria, Belgium, Czechia, Germany, Denmark, Spain, Finland, France, Ireland, Italy, Netherlands, Norway, Poland, Sweden · 154 sites
Registry update: 1 Oct 2026
NCT06943872
Recruiting
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Phase 3 · Argentina, Austria, Australia, Belgium, Brazil, Canada, China, Czechia, Germany, Denmark, Spain, France, United Kingdom, Ireland, Italy, South Korea, Netherlands, New Zealand, Poland, Sweden, United States · 197 sites
Registry update: 23 Oct 2026
NCT06860880
Recruiting
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
Not applicable · United States · 1 site
Registry update: 1 Jul 2026
NCT06839053
Recruiting
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Phase 2 · United States · 1 site
Registry update: 30 Oct 2026
NCT06978088
Recruiting
LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This
Phase 2 · United States · 1 site
Registry update: 14 Aug 2025

Ordered by registry start date. Freshness and sponsorship never change the order.